Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Varegacestat (Gamma Secretase Inhibitor) in Desmoid Tumors. The expected timing is based on the latest available company guidance and may change.
08/11/26:- NDA acceptance and PDUFA April 28, 2027 reiterated. EU MAA planned by end of 2026.
Verification
Confirm timing and program details against the company announcement or filing.